Life Scientist > Lab Technology

SCS signs with Chemicon

07 October, 2005 by Ruth Beran

Stem Cell Sciences (AIM:STEM, SCS) has signed an exclusive agreement with Californian-based stem cells solutions provider Chemicon International, a wholly owned subsidiary of Serologicals Corporation (NASDAQ:SERO), for the manufacture and marketing of SCS' embryonic stem (ES) cell media to the research and drug discovery market.


pSivida secures US$15m, US Medicare rebate approved

07 October, 2005 by Helen Schuller

pSivida has secured US$15 million (AUD$20 million) in additional funding from a New York institutional investor to assist in the development of its platform technology BioSilicon.


In brief: NeuroSolutions, Benitec, Living Cell Technologies, Chemgenex, Life Therapeutics

06 October, 2005 by Helen Schuller and Ruth Beran

UK-based NeuroSolutions, the fully owned subsidiary of NeuroDiscovery (ASX:NDL), has signed its first Australian revenue contract with Perth-based biopharmaceutical company Alzhyme. NeuroSolutions' Alzheimer models will be used to investigate the potential of three Alzhyme peptides to impede the progression of the disease.


Peptech appoints new CEO

06 October, 2005 by Ruth Beran

Sydney's Peptech (ASX:PTD) has appointed Dr John Chiplin as its new chief executive officer, effective January 2006.


EvoGenix to optimise proteins for GlaxoSmithKline

06 October, 2005 by Ruth Beran

GlaxoSmithKline (GSK) and EvoGenix (ASX:EGX) have signed a deal to apply the antibody developer's EvoGene technology to optimise selected compounds from GSK's product pipeline.


Starpharma awarded landmark contract for VivaGel development

05 October, 2005 by Helen Schuller

Melbourne drug developer Starpharma (ASX:SPL) has been awarded a US$20.3 million (AUD$26.4 million) contract from the US National Institutes of Health (NIH), for the development of its HIV preventative product VivaGel.


Prime Minister's prizes for science

05 October, 2005 by Susan Williamson

The annual Prime Minister's prizes for science and science teaching were awarded last night at Parliament House in Canberra.


Orbis acquires 12 per cent of Acrux

05 October, 2005 by Ruth Beran

Bermuda-based investment manager Orbis Mutual Funds has acquired a 12 per cent stake in Melbourne-based drug delivery company Acrux (ASX:ACR).


Resonance Health awarded WA FerriScan supply contract

04 October, 2005 by Helen Schuller and Ruth Beran

Resonance Health Analysis Services (RHAS), a subsidiary of Perth-based Resonance Health (ASX:RHT), has been awarded a health supply contract from the government of Western Australia's department of health, for its FerriScan diagnostic test.


Biotech incubator seeks members

30 September, 2005 by Helen Schuller

A new biotechnology incubator facility due to open in Queensland by the end of this year is calling for companies seeking mentoring and support.


Solbec granted patent

29 September, 2005 by Helen Schuller

Solbec Pharmaceuticals (ASX:SBP) has been granted an Australian patent giving the company the monopoly right to prevent others from isolating the rhamnose binding protein receptor of its lead compound Coramsine.


Phylogica patent allowed

29 September, 2005 by Ruth Beran

Perth-based Phylogica (ASX:PYC) has received formal notice of allowance from the European Patent and Trademark Office for its pending patent application entitled: "Isolating biological modulators from biodiverse gene fragment libraries".


Swinburne develops CD analysis method to aid bioterrorism fight

29 September, 2005 by Helen Schuller

Melbourne's Swinburne University of Technology has developed a rapid method for the analysis of microorganisms on CD or DVD which could be used to detect bioterror agents.


Apollo acquires pre-clinical testing facility

28 September, 2005 by Helen Schuller

Recently listed Sydney biopharma Apollo Life Sciences (ASX:AOP) has acquired a fully operational pre-clinical testing facility in Sydney, including equipment and staff with expertise in targeted and topical drug delivery.


Bone Medical aims to raise $3.1 million

28 September, 2005 by Ruth Beran

Bone disease biopharmaceutical company Bone Medical (ASX:BNE) has issued a prospectus with the aim of raising approximately AUD$3.1 million.


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd